



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

September 23, 2020

RA Session II  
President and Chief Executive Officer  
Taysha Gene Therapies, Inc.  
2280 Inwood Road  
Dallas, TX 75235

**Re: Taysha Gene Therapies, Inc.**  
**Form S-1**  
**Exhibit Nos. 10.1, 10.2, 10.3 and 10.4**  
**Filed September 2, 2020**  
**File No. 333-248559**

Dear Mr. Session:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance